AUVYRON EDUCATION
Tesamorelin: Research Overview
Tesamorelin is a growth hormone–releasing hormone analog studied for its effects on growth hormone signaling, IGF-1 and visceral adipose tissue. Clinical research has focused particularly on adults with HIV-associated lipodystrophy.
Tesamorelin Research Evidence
1. What Tesamorelin Is
3. Major Clinical Programs
1. What Tesamorelin Is
Tesamorelin is a synthetic growth hormone–releasing hormone analog. Published research has examined its effects on growth hormone signaling, IGF-1 levels and visceral adipose tissue, particularly in adults with HIV-associated lipodystrophy.
2. Regulatory Status
3. Major Clinical Programs
1. What Tesamorelin Is
In the United States, tesamorelin is an FDA-approved medication for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. This page summarizes scientific information and does not provide treatment or human-use instructions.
3. Major Clinical Programs
3. Major Clinical Programs
4. Doses Evaluated in Research
Published clinical research on tesamorelin has focused mainly on adults with HIV-associated lipodystrophy. Studies evaluated changes in visceral adipose tissue, IGF-1, lipid parameters and related metabolic measures.
4. Doses Evaluated in Research
4. Doses Evaluated in Research
4. Doses Evaluated in Research
Published clinical studies commonly evaluated tesamorelin at 2 mg administered once daily. These amounts describe published study methodology and are not dosing recommendations.
5. Reported Outcomes
4. Doses Evaluated in Research
5. Reported Outcomes
Clinical trials reported reductions in visceral adipose tissue and improvements in certain body-composition and metabolic measures. Outcomes varied according to the population studied, trial duration and baseline participant characteristics.
6. Safety Findings
4. Doses Evaluated in Research
5. Reported Outcomes
Commonly reported adverse events included injection-site reactions, arthralgia, peripheral edema and glucose-related changes. Tesamorelin research also emphasized the importance of monitoring IGF-1 and overall metabolic response.
Published Research Highlights
1. Phase 3 Clinical Trials
Two multicenter, randomized, double-blind, placebo-controlled studies evaluated tesamorelin in adults with HIV-associated lipodystrophy and excess abdominal fat. Each study included a 26-week main phase and a 26-week extension phase.
2. Visceral Adipose Tissue Outcomes
At 26 weeks, mean visceral adipose tissue decreased by 18% and 14% in the tesamorelin groups across the two pivotal studies, compared with changes of 2% and −2% in the placebo groups.
3. Body-Composition Outcomes
At 26 weeks, the studies reported reductions in trunk fat of approximately 1.0 kg and 0.8 kg, together with increases in lean body mass of approximately 1.3 kg and 1.2 kg. Body weight itself changed very little, reflecting a change in fat distribution rather than general weight loss.
4. Longer-Term Response
Reductions in visceral adipose tissue were maintained in participants who continued tesamorelin through 52 weeks. Participants switched from tesamorelin to placebo experienced regain of visceral fat, suggesting that the observed effect was not maintained after treatment withdrawal.
5. Liver Fat and Metabolic Research
A separate six-month randomized study reported reductions in visceral fat and modest reductions in liver fat. Glucose-related findings varied over time, and the investigators emphasized the need for additional research into the clinical importance and long-term effects.
6. Clinical Context and Limitations
FDA-approved tesamorelin is indicated specifically for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. It is not indicated for general weight-loss management, and its long-term cardiovascular safety has not been established.
Scientific References & Research Disclaimer
1. Research Sources
This guide summarizes peer-reviewed clinical research, FDA-approved prescribing information and published studies related to tesamorelin, HIV-associated lipodystrophy, visceral adipose tissue and metabolic outcomes.
2. Primary Publications
Key sources include pivotal tesamorelin trials, FDA prescribing information and peer-reviewed studies published in journals such as The Journal of Clinical Endocrinology & Metabolism and JAMA.
3. Educational Use
This content is provided for educational and research-information purposes only. Tesamorelin is FDA-approved only for specific use in adults with HIV-associated lipodystrophy. It is not general medical advice, dosing guidance or instructions for human use.
4. Research Use Only
For Research Use Only. Not for Human Consumption.
Quality. Innovation. Excellence.
This website uses cookies.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.